

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

De Angelis 1



Section 1.	Identifying Inform	nation						
1. Given Name (Fi	rst Name)	2. Surname (Last Name) De Angelis	3. Date 28-April-2020					
4. Are you the cor	esponding author? Yes Vo Corresponding Author's Name Martine Piccart-Gebhart							
Cyclin-depender	5. Manuscript Title Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) versus chemotherapy in luminal B early breast cancer. Lessons from the CORALLEEN trial							
6. Manuscript Ider ATM-20-3216	ntifying Number (if you kr	now it)						
Cartinu 2								
Section 2.	The Work Under C	onsideration for Public	tation					
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?								
Are there any relevant conflicts of interest?								
Section 3.	Relevant financial	activities outside the s	submitted work.					
of compensation	the appropriate boxes i) with entities as descri	in the table to indicate who ibed in the instructions. Us	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by the present during the 36 months prior to publication.					
Are there any relevant conflicts of interest?								
Section 4.	Intellectual Proper	rty Patents & Copyric	yhts					
Do you have any	patents, whether plan	ned, pending or issued, br	oadly relevant to the work? Yes V No					

De Angelis 2



Section 5.							
Section 5.	Relationships not covered above						
	relationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?						
Yes, the follo	Yes, the following relationships/conditions/circumstances are present (explain below):						
✓ No other rela	✓ No other relationships/conditions/circumstances that present a potential conflict of interest						
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements Irnals may ask authors to disclose further information about reported relationships.						
Section 6.	Disclosure Statement						
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box						
No conflicts of in	nterest to declare.						

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

De Angelis 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your



Section 1. Identifying Information	ation				
Given Name (First Name) Michail	2. Surname (Last Nar Ignatiadis	me)	3. Date 30-April-202	20	
4. Are you the corresponding author?	Yes ✓ No	Correspon Martine P	ding Author's Name iccart		
5. Manuscript Title Cyclin-dependent kinases 4 and 6 inhibi the CORALLEEN trial	tors (CDK4/6i) versu:	s chemotherapy i	n luminal B early breast cand	cer. Lessons from	
6. Manuscript Identifying Number (if you kno ATM-20-3216	ow it)				
Section 2. The Work Under Co	onsideration for P	ublication			
Did you or your institution at any time received any aspect of the submitted work (including statistical analysis, etc.)?					r
Are there any relevant conflicts of interes	st? ☐ Yes 🗸	No			
Section 3. Relevant financial a	activities outside	the submitted	work.		
Place a check in the appropriate boxes ir of compensation) with entities as described clicking the "Add +" box. You should rep	bed in the instruction	ns. Use one line fo	or each entity; add as many l	ines as you need by	
Are there any relevant conflicts of interes		No		•	
If yes, please fill out the appropriate info	rmation below.				
	Grant? Personal	Non Einancial	7 -		
Name of Entity	Grant Fees?	Support?	Other Comments		
Celgene			✓ Consultancy fees		
Novartis			✓ Consultancy fees		
Pfizer	✓		Consultancy fees, gr institution, travel ex		
Seattle Genetics			✓ Consultancy fees		
Tesaro			✓ Consultancy fees		
Amgen			√ Travel expenses		
Roche			Grant to my instituti	on	



Name of Entity	Grant?	Personal	Non-Financial	Other?	Comments
		Fees?	Support?		
Menarini Silicon Biosystems	✓			✓	Grant to my institution, travel expenses
Section 4. Intellectual Pro	perty Pate	ents & Cop	oyrights		
Do you have any patents, whether p If yes, please fill out the appropriate Excess rows can be removed by pres	information b	elow. If you	•		work? Yes No ty press the "ADD" button to add a row.
Patent? Per	nding?	Licens	ed? Royalties?	License	e? Comments
Patent entitled method for determining sensitivity to a CDK4/6 inh filed the 18 05 16 by Universite Libre de Bruxelles, Application No/Patent No 16170146.1-1403					
Section 5. Relationships n	ot covered	above			
Are there other relationships or active potentially influencing, what you wr				influence	d, or that give the appearance of
Yes, the following relationships/ No other relationships/condition					
At the time of manuscript acceptance On occasion, journals may ask author	-				sary, update their disclosure statements. elationships.

Section 6.

Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Ignatiadis reports other from Celgene, other from Novartis, grants and other from Pfizer, other from Seattle Genetics, other from Tesaro, other from Amgen, grants from Roche, grants and other from Menarini Silicon Biosystems, outside the submitted work; In addition, Dr. Ignatiadis has a patent Patent entitled method for determining sensitivity to a CDK4/6 inh filed the 18 05 16 by Universite Libre de Bruxelles, Application No/Patent No 16170146.1-1403 pending.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

1



Identifying Information

Section 1.

ICMJE Form for Disclosure of Potential Conflicts of Interest

MARTINE	2. Surname (L PICCART	ast Name)		3. Date 14-April-2020		
4. Are you the corresponding author?	✓ Yes	No				
5. Manuscript Title Cyclin-dependent kinases 4 and 6 inhi the CORALLEEN trial	ibitors (CDK4/6i)	versus chemotherapy	in luminal B	early breast cancer. Lessons	from	
6. Manuscript Identifying Number (if you ATM-20-3216	know it)					
Section 2. The Work Under	Consideration	for Publication				
Did you or your institution at any time recany aspect of the submitted work (includir statistical analysis, etc.)?						
Are there any relevant conflicts of inte	rest? Yes	✓ No				
Section 3. Relevant financia	l activities ou	tside the submitted	d work.			
Place a check in the appropriate boxes of compensation) with entities as described the "Add +" box. You should read the second the s	ribed in the inst	ructions. Use one line	for each entit	y; add as many lines as you	need by	
Are there any relevant conflicts of inte		No No				
Name of Entity	Grant•	sonal Non-Financia	Other?	Comments		
Astrazeneca	✓	✓				
Lilly	✓	✓				
MSD	✓	✓				
Novartis	✓	✓				
Pfizer	✓	✓				
Radius	✓					
Roche-Genentech	✓					
Servier	er V					



Name of Entity	Grant? Personal Non-Financia		Other?	Comments	
, in the second second		Fees?	Support?		
Synthon	✓				
Camel-IDS		✓			
Crescendo Biologics		✓			
Debiopharm		\checkmark			
GI Therapeutics		✓			
Huya		✓			
Immunomedics		✓			
Menarini		\checkmark			
Odonate		✓			
Periphagen		✓			
Roche		✓			
Seattle Genetics		✓			
Do you have any patents, whether plann Section 5. Rolationships not of	ed, pend	ing or issue		nt to the	work? ☐ Yes 🗸 No
Relationships not covered above					
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?					
Yes, the following relationships/conditions/circumstances are present (explain below):					
✓ No other relationships/conditions/circumstances that present a potential conflict of interest					
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.					



Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.